PCI Biotech Holding ASA (OSL:PCIB)
Norway flag Norway · Delayed Price · Currency is NOK
1.398
+0.018 (1.30%)
Apr 1, 2025, 11:23 AM CET

PCI Biotech Holding ASA Income Statement

Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Other Revenue
6.742.994.756.277.37
Upgrade
Revenue
6.742.994.756.277.37
Upgrade
Revenue Growth (YoY)
125.25%-37.05%-24.28%-14.86%-21.55%
Upgrade
Gross Profit
6.742.994.756.277.37
Upgrade
Selling, General & Admin
8.639.616.4420.613.92
Upgrade
Research & Development
16.0615.6344.7671.7175.57
Upgrade
Operating Expenses
24.6925.2361.292.389.49
Upgrade
Operating Income
-17.96-22.24-56.45-86.03-82.12
Upgrade
Interest Expense
-0.1-0.16-0.13-0.09-0.4
Upgrade
Interest & Investment Income
1.632.091.240.641.85
Upgrade
Currency Exchange Gain (Loss)
----2.58.5
Upgrade
Other Non Operating Income (Expenses)
--00.24-0.41-0.07
Upgrade
Pretax Income
-16.42-20.32-55.1-88.39-72.24
Upgrade
Net Income
-16.42-20.32-55.1-88.39-72.24
Upgrade
Net Income to Common
-16.42-20.32-55.1-88.39-72.24
Upgrade
Shares Outstanding (Basic)
3737373737
Upgrade
Shares Outstanding (Diluted)
3737373737
Upgrade
Shares Change (YoY)
-0.04%--0.11%-0.01%
Upgrade
EPS (Basic)
-0.44-0.54-1.48-2.37-1.94
Upgrade
EPS (Diluted)
-0.44-0.54-1.48-2.37-1.94
Upgrade
Free Cash Flow
-13.76-14.97-59.04-68.65-81.31
Upgrade
Free Cash Flow Per Share
-0.37-0.40-1.58-1.84-2.18
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-266.59%-743.85%-1188.36%-1371.42%-1114.55%
Upgrade
Profit Margin
-243.76%-679.43%-1159.89%-1409.07%-980.44%
Upgrade
Free Cash Flow Margin
-204.28%-500.67%-1242.99%-1094.34%-1103.56%
Upgrade
EBITDA
-17.65-22.22-56.43-84.11-80.52
Upgrade
EBITDA Margin
-262.09%----
Upgrade
D&A For EBITDA
0.30.020.021.921.6
Upgrade
EBIT
-17.96-22.24-56.45-86.03-82.12
Upgrade
EBIT Margin
-266.59%----
Upgrade
Revenue as Reported
-2.994.756.277.37
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.